Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Non-Current Debt (2021 - 2024)

Historic Non-Current Debt for Pharmaceuticals (CASI) over the last 4 years, with Q2 2024 value amounting to $18.5 billion.

  • Pharmaceuticals' Non-Current Debt changed N/A to $18.5 billion in Q2 2024 from the same period last year, while for Jun 2024 it was $18.5 billion, marking a year-over-year change of. This contributed to the annual value of $18.9 billion for FY2023, which is 15974265.29% up from last year.
  • Pharmaceuticals' Non-Current Debt amounted to $18.5 billion in Q2 2024.
  • In the past 5 years, Pharmaceuticals' Non-Current Debt ranged from a high of $18.9 billion in Q4 2023 and a low of $11.8 million during Q4 2022
  • Moreover, its 4-year median value for Non-Current Debt was $18.6 million (2024), whereas its average is $7.5 billion.
  • Per our database at Business Quant, Pharmaceuticals' Non-Current Debt crashed by 1058.25% in 2022 and then surged by 15974265.29% in 2023.
  • Quarter analysis of 4 years shows Pharmaceuticals' Non-Current Debt stood at $13.2 million in 2021, then decreased by 10.58% to $11.8 million in 2022, then surged by 159742.65% to $18.9 billion in 2023, then decreased by 2.28% to $18.5 billion in 2024.
  • Its Non-Current Debt was $18.5 billion in Q2 2024, compared to $18.6 million in Q1 2024 and $18.9 billion in Q4 2023.